Net sales grew 7.5% to EUR 603 million in H1 2026, with EBITDA margin reaching 25% and strong European dermatology performance. Guidance for 2026 is reiterated, with key products Ilumetri and Ebglyss maintaining momentum and a robust pipeline advancing in immune-mediated skin diseases.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.